Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
The Oncologist2022Vol. 27(7), pp. 536–e553
Citations Over TimeTop 10% of 2022 papers
Judy Wang, Patricia Martín-Romano, Philippe A. Cassier, Melissa L. Johnson, Eric B. Haura, Laurie Lenox, Yue Guo, Nibedita Bandyopadhyay, Michael J. Russell, Elizabeth Shearin, Josh Lauring, Laëtitia Dahan
Abstract
NCT04006301.
Related Papers
- → Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer(2021)37 cited
- → Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.(2020)3 cited
- → Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer(2020)2 cited
- → Lung Cancer and <i>KRAS</i> -Its Molecular Biology/Genetics and Therapeutic Strategy-(2022)
- → 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinoma(2022)